Sophorolipids Decrease IgE Production in U266 Cells

Sophorolipids: A comprehensive review on properties and applications

Sophorolipids are surface-active glycolipids produced by several non-pathogenic yeast species and are widely used as biosurfactants in several industrial applications. Sophorolipids provide a plethora of benefits over chemically synthesized surfactants for certain applications like bioremediation, oil recovery, and pharmaceuticals. They are, for instance less toxic, more benign and environment friendly in nature, biodegradable, freely adsorb to different surfaces, self-assembly in hydrated solutions, robustness for industrial applications etc. These miraculous properties result in valuable physicochemical attributes such as low critical micelle concentrations (CMCs), reduced interfacial surface tension, and capacity to dissolve non-polar components. Moreover, they exhibit a diverse range of physicochemical, functional, and biological attributes due to their unique molecular composition and structure. In this article, we highlight the physico-chemical properties of sophorolipids, how these properties are exploited by the human community for extensive benefits and the conditions which lead to their unique tailor-made structures and how they entail their interfacial behavior. Besides, we discuss the advantages and disadvantages associated with the use of these sophorolipids. We also review their physiological and functional attributes, along with their potential commercial applications, in real-world scenario. Biosurfactants are compared to their man-made equivalents to show the variations in structure-property correlations and possible benefits. Those attempting to manufacture purported natural or green surfactant with innovative and valuable qualities can benefit from an understanding of biosurfactant features structured along the same principles. The uniqueness of this review article is the detailed physico-chemical study of the sophorolipid biosurfactant and how these properties helps in their usage and detailed explicit study of their applications in the current scenario and also covering their pros and cons.

Biosurfactants and anti-inflammatory activity: A potential new approach towards COVID-19

Coronavirus disease 2019 (COVID-19) has grown to be global public health emergency. The biosurfactants (BSs) are surface-active biomolecules with unique properties and wide applications. Several microbes synthesize secondary metabolites with surface-active properties, which have a wide range of anti-inflammatory and anti-viral roles. The monocytes and neutrophils are activated by bacteria, which subsequently result in high secretion of pro-inflammatory cytokines (TNF-α, IL-6, IL-8, IL-12, Il-18 and IL-1β) and toll-like receptors-2 (TLR-2). Following the inflammatory response, BSs induce the production of cationic proteins, reactive oxygen species (ROS) and lysozyme, and thus can be used for therapeutic purposes. This article provides recent advances in the anti-inflammatory and antiviral activities of BSs and discusses the potential use of these compounds against COVID-19, highlighting the need for in-vitro and in-vivo approaches to confirm this hypothesis. This suggestion is necessary because there are still no studies that have focused on the use of BSs against COVID-19.

Sophorolipids Improve Sepsis Survival: Effects of Dosing and Derivatives

INTRODUCTION

Sophorolipids, a family of natural and easily chemo-enzymatically modified microbial glycolipids, are promising modulators of the immune response. We have previously demonstrated that sophorolipids mediate anti-inflammatory effects, including decreasing sepsis-related mortality at 36 h in vivo in a rat model of septic peritonitis and in vitro by decreasing nitric oxide and inflammatory cytokine production. Here we assessed the effect of sophorolipids on sepsis-related mortality when administered as a (1) single bolus versus sequential dosing and (2) natural mixture versus individual derivatives compared with vehicle alone.

METHODS

Intra-abdominal sepsis was induced in male, Sprague Dawley rats, 200 to 240 g, via cecal ligation and puncture. Sophorolipids (5-750 mg/kg) or vehicle (ethanol/sucrose/physiological saline) were injected intravenously (i.v.) via tail vein or inferior vena cava at the end of the operation either as a single dose or sequentially (q24 h x 3 doses); natural mixture was compared with select sophorolipid derivatives (n = 10-15 per group). Sham-operated animals served as nonsepsis controls. Survival rates were compared at 1 through 6 d post sepsis induction and tissue was analyzed by histopathology. Significance was determined by Kruskal-Wallis analysis with Bonferroni adjustment and Student's t-test.

RESULTS

Sophorolipid treatment at 5 mg/kg body weight improved survival in rats with cecal ligation and puncture-induced septic shock by 28% at 24 h and 42% at 72 h for single dose, 39% at 24 h and 26% at 72 h for sequential doses, and 23% overall survival for select sophorolipid derivatives when compared with vehicle control (P < 0.05 for sequential dosing). Toxicity was evident and dose-dependent with very high doses of sophorolipid (375-750 mg/kg body weight) with histopathology demonstrating interstitial and intra-alveolar edema with areas of microhemorrhage in pulmonary tissue when compared with vehicle controls (P < 0.05). No mortality was observed in sham operated controls at all doses tested.

CONCLUSIONS

Administration of sophorolipids after induction of intra-abdominal sepsis improves survival. The demonstration that sophorolipids can reduce sepsis-related mortality with different dosing regimens and derivatives provides continuing evidence toward a promising new therapy. Toxicity is evident at 75 to 150x the therapeutic dose in septic animals.